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Introduction
Persistent patent ductus arteriosus (PDA) is frequently
encountered in preterm infants. A variety of morbidi-
ties such as necrotizing enterocolitis (NEC) and bron-
chopulmonary dysplasia arise because of failure of
closure of the ductus arteriosus (DA).1 Therefore, clo-
sure of the PDA is crucial in the care of prematurity,
especially for extremely-low-birth-weight (ELBW) neo-
nates (birth body weight < 1,000 g) who are prone to
long-term sequelae if the clinical course is complicated
by PDA.
Indomethacin has been used since the early 1970s
for this purpose, and intravenous (IV) indomethacin
is a standard medical treatment, with effectiveness up
to 70–80%.2–4 However, if the IV form is not available,
oral indomethacin is a potential alternative. Several
previous studies have reported a poor response to 
oral indomethacin due to marked variability in the
serum concentrations of indomethacin.5,6 In contrast,
Mrongovius et al reported that both the rates of per-
manent closure and transient closure were similar in
either the IV route or oral route and the closure rate
was independent from serum concentrations.7 Scanlon
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showed that an 85% closure rate was achieved with an
ethanol-based oral solution.8 It is not clear whether
using a base-aqueous solution or ethanol makes any
difference. Therefore, we compared the effectiveness of
oral ethanol-based indomethacin and IV indomethacin
for PDA closure in ELBW infants.
Methods
Study infants and design
This was a retrospective chart review study. The study
subjects included ELBW infants who were treated with
indomethacin due to hemodynamic significant PDA.
All these babies were born between July 1997 and
June 2007 at Taipei Veterans General Hospital, Taiwan.
Hemodynamically significant PDA was defined as the
presence of any of the following signs: systolic or con-
tinuous murmur together with widening of pulse
pressure or active precordial heave, cardiomegaly and
increased pulmonary vascularity on chest radiography,
and failure to wean from mechanical ventilation. ELBW
infants with other congenital diseases such as congen-
ital heart disease other than PDA and congenital renal
disease were excluded from the study.
Before initiation of indomethacin treatment, serum
creatinine levels, platelet count, total bilirubin and
electrolytes were assessed. Therapy was given if the
platelet count was > 50,000/μL, serum creatinine lev-
els were < 1.5 mg/dL, or urine output was > 1 mL/kg
per hour in the preceding 8 hours. During the treat-
ment, when urine output declined below 1 mL/kg
per hour, furosemide 0.5–1.0 mg/kg was given. After
treatment, serum creatinine was assessed again, and
fluid and electrolyte administration was adjusted accord-
ing to the daily variation of body weight and serum
electrolytes. In case of adverse events such as intraven-
tricular hemorrhage grade III or higher, gastrointesti-
nal bleeding, or perforation and NEC, indomethacin
was withheld until clinical status improved. Cranial
ultrasonography was performed before and after every
treatment course.
Diagnosis of PDA and follow-up
The diagnosis of PDA was confirmed by echocardiog-
raphy with the demonstration of left-to-right blood
flow through the open duct. The ductal size was
measured with a 2-dimensional image through the
parasternal short-axis view. The size and ejection frac-
tion of the left ventricular chamber was also measured
by cardiography. Color and pulsed wave spectral
Doppler scanning was applied to assess the direction
and the velocity of ductal flow. After every treatment
course, echocardiography was repeated to confirm
the closure of ductus, which was defined as a ductal
diameter < 1 mm or a tiny blood jet. If echocardiogra-
phy indicated ductus closure, daily assessment of heart
murmur was performed.
Indomethacin treatment regimen
The choice of either the IV route or oral route depended
on the policy of in-charge attending physicians. In the
enteral group, indomethacin was prepared by dissolv-
ing a 25-mg indomethacin capsule with beer to a final
concentration of 1 mg/mL. IV regimen of indome-
thacin (1 mg/mL, Indocid PDA; Merck Sharp &
Dohme, Hertfordshire, UK) was diluted in distilled
water to a final concentration of 0.1mg/mL and infused
over 30 minutes. Every course included 3 doses at a
dosage of 0.2 mg/kg. The same dose was repeated 
12 hours and 24 hours later if the urine amount was
not less than 1 mL/kg per hour; however, if the urine
volume was less, the interval was prolonged. Echo-
cardiography was conducted 24–36 hours after com-
pletion of the course. In treatment failure cases, another
course of treatment was administrated through the same
route. The treatment was delayed when any of the
following conditions were present: unstable hemody-
namic status; progressive, active bleeding diathesis;
urine amount < 1 mL/kg/hr; serum creatinine level
> 1.5 mg/dL; significant hyperbilirubinemia near
exchange transfusion level or NEC. Surgical ligation
was attempted if a total of 3 courses failed to close 
the PDA.
Data collection
The following information was collected: the response
to the 1st course of indomethacin (closed or open), the
need for a 2nd or 3rd course, the cases of surgical liga-
tions, and the side effects of indomethacin. Anticipated
adverse effects were oliguria (urine output < 1 mL/kg
per hour for the following 8 hours), post-treatment
serum creatinine levels > 1.5 mg/dL, serum sodium
< 130 mmol/L or a decrease in serum sodium of more
than 5 mmol/L when compared with pretreatment
values, coffee ground aspirate, and fresh blood from
the gastric tube. These side effects were attributed to
indomethacin if they occurred during the treatment
course or within 48 hours after treatment.
Potential confounding factors such as daily fluid
intake, the setting of mechanical ventilation, surfac-
tant use, antenatal steroids and culture-proven sepsis,
were examined in the study. Various clinical outcomes
such as days on oxygen supplement or mechanical
ventilation, chronic lung disease (CLD), retinopathy
of prematurity (ROP), intraventricular hemorrhage,
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cystic periventricular leukomalacia (PVL), and NEC
were recorded. PVL was defined as periventricular
hyperechogenicity that progressed to cyst formation.
Statistical analysis
Numeric data expressed as the mean with standard
deviation or median with range were compared by
Student’s t test. Fisher’s exact test was used for the
comparison of non-numeric data. The Mann-Whitney
test was used for non-parametric data. Statistical sig-
nificance was set at p < 0.05. All statistical analyses
were performed with SPSS version 15 (SPSS Inc.,
Chicago, IL, USA).
Results
In total, there were 144 ELBW infants born between
July 1997 and June 2007 and 72 cases survived; 41
ELBW infants had PDA and 29 of these infants survived
(28.5%/40.1% of PDA in this total/survival group).
Spontaneous closure without indomethacin treatment
occurred in 3 patients and 3 patients died before
treatment administration. The gestational ages and
body weights at birth of these 3 infants with sponta-
neous closure were 25, 29, 27 weeks and 698, 924,
770 g, respectively. These infants did not receive indo-
methacin treatment because of their stable condition
without ventilator support at the age of PDA diag-
nosis, and they had PDA closure just with fluid
restriction. The remaining 35 infants were treated with
indomethacin. Thirteen infants received oral ethanol-
based solution and 22 infants received the IV form.
There were 9 mortality cases all due to sepsis. There
were no significant differences in clinical characteris-
tics between the enteral and IV groups (Table 1).
The courses and responses to indomethacin ther-
apy are shown in Table 2. Both the total closure rate
and the response rates to the 1st treatment course were
higher in the IV group than in the enteral group, but
this was not significantly different. In the IV group, 2
infants received surgical ligation at the postnatal ages
of 32 and 38 days after 3 treatment courses, and extu-
bation was successful on the 2nd day after operation.
In the enteral group, 4 cases did not receive the full
treatment courses despite their persistent PDA; 3 of
them received 2 courses and 1 case received 1 course
only because of severe oliguria and sepsis. The infant
with 1 course had intermittent mandatory ventilation
for 6 days and then died. The other 3 infants were
ventilator-dependent for 40, 50 and 56 days, and they
had PDA closure before discharge (p=0.0437). Surgical
J Chin Med Assoc • January 2010 • Vol 73 • No 1 17
IV and enteral indomethacin for PDA closure
Table 1. Clinical characteristics of the study population*
Enteral group (n = 13) IV group (n = 22) p
GA (wk) 26 ± 2.3 27 ± 2.5 0.11
BBW (g) 833.7 ± 110.3 807.4 ± 146.8 0.58
Sex 0.41
Male 3 8
Female 10 14
Twin/triple pregnancy 5 (33.3) 8 (36.4) 0.73
Apgar score
1-min 3 (1–7) 4 (1–7) 0.73
5-min 6 (5–8) 6 (1–9) 0.47
RDS
I/II 7 (46.7) 11 (50) 0.82
II/III 8 (53.3) 11 (50) 0.82
Surfactant 10 (66.7) 17 (77.2) 0.32
Ductal size (cm) 0.25 ± 0.12 0.18 ± 0.08 0.10
Age at diagnosis (d) 9 (1–28) 5 (2–32) 0.73
Age at therapy (d) 11 (3–28) 7 (2–57) 0.96
Antenatal steroid 1 (6.7) 4 (18.2) 0.39
*Data presented as mean ± standard deviation or n or n (%) or median (range). IV = intravenous; GA = gestational age; BBW = birth body weight; RDS = respiratory
distress syndrome.
ligation was not attempted in these 3 cases because of
unstable condition.
The occurrence rate of oliguria and upper gastro-
intestinal hemorrhage was higher in the IV than in the
enteral group, but this was not statistically significant.
However, the incidence of impaired renal function,
such as elevated creatinine level, electrolyte imbalance
or NEC, was similar in both groups (Table 3). Enteral
patients had a longer dependence on continuous pos-
itive airway pressure (CPAP), a higher rate of CLD at
a gestational age of 36 weeks, and a higher incidence of
ROP and PVL (Table 4), but none of these differences
were statistically significant.
Discussion
The effect of indomethacin on PDA closure appears
to be related to drug concentration, drug exposure
time9 and host constitution. IV indomethacin is a well-
accepted medical treatment for PDA closure;10 how-
ever, the effects of the enteral form of indomethacin
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Table 2. Responses to indomethacin therapy by treatment group*
Enteral group (n = 13) IV group (n = 22) p
Closure 10 (76.9) 18 (81.8) 0.72
1st course 7 (46.7) 13 (59.1) 0.76
2nd course 1 (61.5)† 2 (68.2)† 0.69
3rd course 2 3
Ligation 0 2 0.52
Closed after conservative treatment 3 0 0.04
Mortality 2 7 0.43
*Data presented as n (%) or n; †cumulative percentage. IV = intravenous.
Table 3. Adverse events during indomethacin therapy by treatment group*
Enteral group (n = 13) IV group (n = 22) p
Urine < 1 mL/kg/hr 2 (13.3) 6 (27.2) 0.35
Serum Cr > 1.5 mg/dL 4 (26.6) 3 (13.6) 0.29
GI hemorrhage 4 (26.6) 12 (54.5) 0.13
Necrotizing enterocolitis 3 (20) 4 (18.2) 0.51
Hyponatremia 3 (20) 3 (13.6) 0.44
*Data presented as n (%). IV = intravenous; Cr = creatinine; GI = gastrointestinal.
Table 4. Neonatal outcomes by treatment group*
Enteral group (n = 13) IV group (n = 22) p
O2 supplement (d) 41.2 ± 26.3 38.6 ± 28.6 0.79
CPAP (d) 27.8 ± 26.4 18.7 ± 14.4 0.21
IMV (d) 24.1 ± 27.5 20.4 ± 22.8 0.68
CLD at 36 wk gestation 7 (53.8) 7 (31.8) 0.53
ROP (stage III/IV) 2 (15.4) 1 (4.5) 0.67
IVH 6 (46.2) 7 (31.8) 0.64
PVL 3 (23.1) 2 (9.1) 0.35
Sepsis 4 (30.8) 9 (40.9) 0.58
NEC 3 (23.1) 5 (22.7) 0.86
Full feeding (d) 49.6 ± 37.8 36.4 ± 37.1 0.33
*Data presented as mean ± standard deviation or n (%). IV = intravenous; CPAP = continuous positive airway pressure; IMV = intermittent mandatory ventilation;
CLD = chronic lung disease; ROP = retinopathy of prematurity; IVH = intraventricular hemorrhage; PVL = periventricular leukomalacia; NEC = necrotizing 
enterocolitis.
are still controversial, possibly because of its high vari-
ability of pharmacodynamics in preterm babies. To
our knowledge, there are very few studies that have
compared the effectiveness of the IV and enteral forms
of indomethacin for PDA closure in ELBW infants.
Cooke and Pickering reported 5 cases of treatment
failure in 7 very-low-birth-weight infants who had an
oral aqueous solution.5 Earlier pharmacokinetic stud-
ies by Bhat et al11 and Evans et al12 reported that the
absorption of oral indomethacin in preterm neonates
with PDA was low and erratic. However, later clinical
studies reported a 70% closure rate with an aqueous
solution.13 The greater effectiveness of an ethanol-
based solution has been demonstrated by Scanlon who
found an 85% closure rate.8 A possible factor that
might influence the outcome is the preparation solu-
tion of the enteral indomethacin. Previous studies have
shown a large interindividual variability in plasma con-
centrations of indomethacin with an aqueous solu-
tion, and the in vitro bioavailability was approximately
20%.6,11,12 Scanlon demonstrated that diluting indo-
methacin in water would consistently underdose, and
the percent variance from the mean was almost triple
that for ethanol.8 Recently, a pharmacokinetic study
reported that a saline-ethanol-dextrose suspension
achieved a 98.6% absorption rate in preterm infants;
this finding provided evidence that preterm infants could
be switched between the IV and orogastric routes.14
In this study, the enteral method used ethanol-based
indomethacin, and the closure rate was 76.9% compared
with 81.8% using the IV form; there was no significant
difference between the 2 routes of administration.
The incidence of oliguria and impaired renal func-
tion was similar in both groups. This finding may be
explained from the pharmacokinetic standpoint since
some studies have reported that no definite relation-
ship exists between drug concentration and PDA clo-
sure7,15–17 as well as kidney function.7 Previous reports
have documented the increased incidence of CLD
due to persistent PDA,18,19 as well as CLD, severe ROP
and PVL among infants exposed to indomethacin.20
In this study, the enteral group had a longer depend-
ence on CPAP and a trend for an increased incidence of
CLD, severe ROP and PVL. However, because there
was an insufficient number of cases, these differences
were not statistically significant. The causal relationship
between these findings requires further investigation.
Surgical ligation should be considered if medical
therapy has failed or the patient’s status is not suitable
for indomethacin therapy. Keller and Clyman suggested
that additional indomethacin treatment is unlikely to
produce ductus closure in premature infants if there 
is persistent Doppler evidence of ductal flow within 
24 hours after an initial short course, and earlier sur-
gical ligation is suggested.21 A recent study questioned
the long-term safety of more than 2 courses of indo-
methacin in preterm infants.22 However, a survey of
Neonatal Fellowship Program Directors in the United
States reported that multiple courses of indomethacin
(up to 3 courses) are commonly used for persistent
PDA.23 There is still debate on whether surgical liga-
tion or multiple courses of indomethacin should be
the preferred treatment if the PDA fails to close after
the initial course. In our study, 2 patients in the IV
group received surgical ligation due to failure of extu-
bation and persistent dyspnea after 3 full courses of
indomethacin. Both of the patients were extubated
on the 2nd day after surgery and were soon independ-
ent from oxygen and the ventilator. Four patients in
the enteral group did not undergo surgical ligation
after medical therapy failure due to sepsis. Except for
1 case who died before PDA closure, the other 3 cases
were extubated soon after sepsis resolved and had spon-
taneous PDA closure after infection control; however,
they had a much longer dependence on CPAP with a
ventilator and oxygen. It remains a challenge for the
clinician to determine what is the best time point for
surgery or whether to just give conservative therapy.
There were some limitations in this study. Because
of the retrospective design, there was a latent short-
age of homogeneity in patient data, and the case num-
bers in both groups were insufficient. Although this
was a retrospective study, the findings were from a
single unit over a 10-year period. There were no major
changes in clinical practice during this study period.
This study showed that the outcome of treatment
with an enteral preparation of ethanol-based indome-
thacin was comparable to that of the IV preparation.
This finding suggests that ethanol-based indomethacin
is an effective alternative to IV indomethacin for the
pharmacological closure of PDA in ELBW infants.
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